Shares of Epizyme Inc (NASDAQ:EPZM) have been assigned an average rating of “Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $19.00.
EPZM has been the subject of several research reports. Cowen reissued a “buy” rating and issued a $18.00 target price on shares of Epizyme in a report on Tuesday, February 26th. BidaskClub downgraded Epizyme from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 23rd. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research note on Tuesday, April 30th. HC Wainwright set a $25.00 price objective on Epizyme and gave the company a “buy” rating in a research note on Friday, May 31st. Finally, Roth Capital reaffirmed a “buy” rating on shares of Epizyme in a research note on Wednesday, February 27th.
Shares of Epizyme stock traded down $0.28 on Tuesday, hitting $14.03. The stock had a trading volume of 897,517 shares, compared to its average volume of 855,333. Epizyme has a 52-week low of $5.14 and a 52-week high of $16.95. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.55 and a current ratio of 12.55. The company has a market capitalization of $1.30 billion, a P/E ratio of -8.16 and a beta of 2.72.
Epizyme (NASDAQ:EPZM) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.46) by $0.07. The firm had revenue of $7.89 million during the quarter, compared to analysts’ expectations of $1.13 million. As a group, analysts forecast that Epizyme will post -2 earnings per share for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the business. Exane Derivatives purchased a new position in shares of Epizyme during the 1st quarter worth approximately $84,000. Quantamental Technologies LLC purchased a new position in shares of Epizyme during the 4th quarter worth approximately $43,000. Legal & General Group Plc raised its stake in shares of Epizyme by 16.9% during the 4th quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 1,455 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of Epizyme during the 1st quarter worth approximately $135,000. Finally, Two Sigma Advisers LP purchased a new position in shares of Epizyme during the 4th quarter worth approximately $76,000. 84.14% of the stock is owned by hedge funds and other institutional investors.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Further Reading: Is it Safe to Invest in Commodities?
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.